2500674-05-3
Chemical Structure
Pertuzumab zuvotolimod
Synonym(s): SBT6050
- CAS No.: 2500674-05-3
- Molecular Weight:N/A
IUPAC Name: 2-(3,4-dihydroxybenzyl)-2-hydrazinylpropanoic-3-13C-3,3,3-d3 acid
SMILES: [Pertuzumab zuvotolimod]
Biological Activity: Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod activates TLR8 in human myeloid cells in a myeloid Fcγ receptor-dependent manner in the presence of HER2-positive tumor cells, driving antitumor immunity. Pertuzumab zuvotolimod repolarizes suppressive myeloid cells to a pro-immunogenic phenotype and induces tumor-specific cytotoxic T lymphocyte responses. Pertuzumab zuvotolimod shows single-agent activity in HER2-positive syngeneic tumor models and induces long-lasting immune memory without triggering peripheral cytokine production or CRS-like toxicity. Pertuzumab zuvotolimod can be used for research on HER2-positive solid tumors and HER2-expressing tumors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pertuzumab zuvotolimod | 98.64% | Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod activates TLR8 in human myeloid cells in a myeloid Fcγ receptor-dependent manner in the presence of HER2-positive tumor cells, driving antitumor immunity. Pertuzumab zuvotolimod repolarizes suppressive myeloid cells to a pro-immunogenic phenotype and induces tumor-specific cytotoxic T lymphocyte responses. Pertuzumab zuvotolimod shows single-agent activity in HER2-positive syngeneic tumor models and induces long-lasting immune memory without triggering peripheral cytokine production or CRS-like toxicity. Pertuzumab zuvotolimod can be used for research on HER2-positive solid tumors and HER2-expressing tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Azzawi M A. The role of novel Pan-HER tyrosine kinase inhibitors and immune system-based biomarkers of response in oesophageal and gastric cancer[D].
- [2]. Xia X, et al. The History and Development of HER2 Inhibitors. Pharmaceuticals (Basel, Switzerland). 2023 Oct 12;16(10):1450.
- [3]. Moyes K, et al. A systemically administered, conditionally active TLR8 agonist for the treatment of HER2-expressing tumors[J]. Cancer Research, 2019, 79(13_Supplement): 3271-3271.
